Synovial sarcoma
MONDO:0010434Synovial sarcoma is an aggressive soft tissue sarcoma, occurring most commonly in adolescents and young adults (15 to 40 years), usually localized near the large joints of the extremities but also in the head and neck, mediastinum and viscera (lung, kidney etc), clinically presenting as a deep seated swelling or a painful mass often with an initial indolent course and is characterized by its local invasiveness and a propensity to metastasize. The origin of synovial sarcoma is likely from multipotent mesenchymal cells and not synovium (contrary to its name).
Also known as: SS, Synovialosarcoma, sarcoma, synovial, malignant, synovial sarcoma, synovial sarcoma (disease), sarcoma, synovial
2863 clinical trials for this condition and its sub-types, 53 tagged with Synovial sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Synovial sarcoma
-
Biphasic synovial sarcoma 0 trials
-
Breast synovial sarcoma 0 trials
-
Fibrous synovial sarcoma 0 trials
-
Mediastinum synovial sarcoma 0 trials
-
Monophasic synovial sarcoma 0 trials
2 sub-types
- Epithelioid cell synovial sarcoma 0 trials
- Spindle cell synovial sarcoma 0 trials
-
Genetically modified t cells take on rare sarcomas
Disease control OngoingThis phase 2 trial tests a one-time infusion of a patient's own immune cells that have been genetically modified to recognize and attack cancer cells. It is for people with advanced synovial sarcoma or myxoid liposarcoma whose tumors have a specific marker (MAGE-A4) and who have …
Phase 2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat cancers
Disease control OngoingThis study tests a new treatment using a patient's own immune cells that are genetically modified to better recognize and attack certain solid tumors. It is for people with advanced cancers like synovial sarcoma that have not responded to other treatments. The goal is to see if t…
Phase 2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug duo takes on rare sarcomas
Disease control OngoingThis phase 2 trial tests whether combining NKTR-214 and nivolumab can shrink or control advanced sarcoma that has spread. About 88 people aged 12 and older with certain sarcoma types will receive both drugs every three weeks. The main goal is to see how many patients have their t…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control OngoingThis trial investigates a new type of immunotherapy for people with advanced cancers that carry a specific marker called NY-ESO-1. Researchers take a patient's own T cells, modify them in the lab to better recognize and attack cancer cells, and then infuse them back. The study al…
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental drug tazemetostat offered to patients with rare, aggressive tumors
Disease control Expanded access (ended)This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells take aim at multiple cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …
Phase 1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take aim at childhood cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo shows promise for Hard-to-Treat sarcomas
Disease control OngoingThis study tests whether combining two drugs, lenvatinib and pembrolizumab, can safely shrink or control advanced soft tissue sarcomas that have spread or can't be removed by surgery. About 52 adults with specific sarcoma types will receive the combination. The goal is to measure…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New radioactive drug targets childhood cancers that Won't quit
Disease control OngoingThis early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…
Phase 1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental combo aims to boost immune attack on sarcoma before surgery
Disease control OngoingThis early-phase study tests the safety of combining two immunotherapy drugs—nivolumab and BO-112—given before surgery for soft tissue sarcoma that can be removed. About 14 adults with certain sarcoma types will receive these drugs to see if they help the immune system fight the …
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control CancelledThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Engineered immune cells take on childhood cancers in first human test
Disease control OngoingThis early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells ca…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC